Specialty drugmaker Mallinckrodt (MNK) announced a $2.3 billion deal Thursday to acquire privately held Ikaria, which was greeted with enthusiasm on the stock market. Ikaria makes INOmax, an inhaled nitric oxide used to treat newborns with respiratory problems. Mallinckrodt said the deal will expand its hospital business, adding $150 million and 25 cents a share to its 2015 financials. “This product has been growing sales slow and steady in the
Specialty-drug maker Mallinckrodt (MNK) reported mixed fiscal Q1 results Tuesday, sending the stock down as much as 6%. In the quarter ended Dec. 26, Mallinckrodt’s earnings excluding one-time items more than doubled over the year-earlier quarter to $1.84 a share, beating analysts’ consensus by 26 cents. Sales rose 60% to $866.3 million, about $20 million short of the Street’s average estimate. The company didn’t offer any new guidance, but on the
Specialty drugmaker Mallinckrodt early Wednesday beat analysts’ expectations handily with its fiscal Q4 report, but the stock fell 3.2% after the company put off providing hoped-for guidance in the wake of a Food and Drug Administration decision that hits one of its best-selling drugs. For its fiscal fourth quarter, which ended Sept. 26, Mallinckrodt (MNK) made $1.68 a share excluding one-time items, up 71% from the year-earlier quarter and 27